Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5551997 | 0.80 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL3401752 | 0.79 | TSHR (0.51) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL29354025 | 0.79 | TSHR (0.51) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| 2-Methyl-D-Diboa SCHEMBL13135829 | 0.78 | ALDH1A1 (0.54) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL22770046 | 0.76 | TSHR (0.37) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL22770045 | 0.76 | TSHR (0.37) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7349339 | 0.75 | PDE3B (0.49) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL21483641 | 0.75 | TSHR (0.62) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL7340192 | 0.75 | PDE3B (0.53) | TSHRMEN1KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL5159362 | 0.72 | TSHR (0.58) | TSHRMEN1KMT2AALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868749-B2 | Fused imidazole and pyrazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-01-16 | — | — | US | disclosed |
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | EVOTEC (UK) LTD. (GB) | 2016-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297837-A1 | Fused Imidazole and Pyrazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | TSHR 753/4885MEN1 3434/4885KMT2A 4312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.